This work not only provides new insights into our understanding of the dephosphorylation events in TGF-β signaling and expands our knowledge of anti-tumor signaling actions of RGS6, but also provide solid evidence supporting RGS6 as a prognostic marker and a potential novel target for NSCLC therapy. Here, RGS6 is linked to neoplasm.